- Home
- FENC vs SGHT Comparison
FENC vs SGHT Comparison
Compare FENC & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- SGHT
- Stock Information
- Founded
- FENC 1996
- SGHT 2011
- Country
- FENC United States
- SGHT United States
- Employees
- FENC N/A
- SGHT N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- SGHT Medical Specialities
- Sector
- FENC Health Care
- SGHT Health Care
- Exchange
- FENC Nasdaq
- SGHT Nasdaq
- Market Cap
- FENC 156.9M
- SGHT 157.7M
- IPO Year
- FENC 2001
- SGHT 2021
- Fundamental
- Price
- FENC $8.07
- SGHT $3.91
- Analyst Decision
- FENC Strong Buy
- SGHT Buy
- Analyst Count
- FENC 2
- SGHT 7
- Target Price
- FENC $13.00
- SGHT $4.02
- AVG Volume (30 Days)
- FENC 105.2K
- SGHT 182.9K
- Earning Date
- FENC 05-13-2025
- SGHT 05-08-2025
- Dividend Yield
- FENC N/A
- SGHT N/A
- EPS Growth
- FENC N/A
- SGHT N/A
- EPS
- FENC N/A
- SGHT N/A
- Revenue
- FENC $30,912,000.00
- SGHT $78,109,000.00
- Revenue This Year
- FENC N/A
- SGHT N/A
- Revenue Next Year
- FENC $58.65
- SGHT $11.68
- P/E Ratio
- FENC N/A
- SGHT N/A
- Revenue Growth
- FENC N/A
- SGHT N/A
- 52 Week Low
- FENC $3.96
- SGHT $2.03
- 52 Week High
- FENC $8.56
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- FENC 66.93
- SGHT 63.75
- Support Level
- FENC $7.79
- SGHT $3.36
- Resistance Level
- FENC $8.34
- SGHT $3.75
- Average True Range (ATR)
- FENC 0.46
- SGHT 0.26
- MACD
- FENC 0.06
- SGHT 0.02
- Stochastic Oscillator
- FENC 76.75
- SGHT 85.37
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.